Novo Nordisk is undergoing a significant transformation under the leadership of its new chief executive, Jesper Doustdar, who took the helm in August 2025 amid a series of organizational upheavals. The pharmaceutical company, known globally for pioneering weight-loss drugs in the GLP-1 class, has faced mounting challenges including declining market share, profit warnings, legal disputes, and a high-profile boardroom reshuffle.

The previous CEO was ousted by the company’s main shareholder, the Novo Nordisk Foundation, which also saw the resignation of the company’s chair and all independent board members last year. The foundation’s chair, Lars Rebien Sorensen—a former CEO of Novo Nordisk—subsequently assumed the chairmanship of the company’s board, a move that generated unease among some investors, including Norway’s sovereign wealth fund.

Novo Nordisk’s recent difficulties stem largely from intensifying competition, notably from Eli Lilly, and the growing presence of lower-cost alternatives from compounding pharmacies. The company responded with one of the largest corporate restructurings in Danish history, cutting approximately 9,000 jobs. Doustdar, the company’s first non-Danish CEO, has sought to reinvigorate the organization by shifting its focus toward serving a broader customer base beyond traditional patients. He has emphasized accessibility, including prescriptions without in-person doctor visits, aiming to address stigma surrounding weight-related health issues.

This customer-centric approach has sparked debate about whether Novo Nordisk is moving toward a cosmetically oriented market. Doustdar dismissed this notion as a distraction, emphasizing the scientific rigor and safety of their products and the genuine need among diverse users.

Under Doustdar’s leadership, the company has also adopted a more aggressive commercial posture, especially in the U.S., which now accounts for a majority of its sales. Novo Nordisk has rebranded Rybelsus—the first semaglutide pill approved for Type 2 diabetes—in the U.S. as “the Ozempic pill” to leverage greater brand recognition. The company has also escalated legal actions, filing lawsuits against numerous firms and recently suing Eli Lilly over alleged deceptive advertising practices.

The company’s evolving footprint also reflects a geographic shift, with U.S. operations expanding while Danish employment contracts. A $4 billion investment in new manufacturing facilities in North Carolina underscores its commitment to the American market. Novo Nordisk produces its weight-loss medication Wegovy entirely in the U.S. through facilities in Clayton and Durham.

Despite these efforts, investor confidence remains cautious. Doubts arose after the company’s recent trial failures for its next-generation weight-loss drug, CagriSema, which did not demonstrate superior efficacy compared to Eli Lilly’s existing competitor. Market experts and some investors, such as Hassan Chowdhry of GMO Asset Management, have tempered expectations for Novo Nordisk’s near-term growth, noting the absence of a clear catalyst to boost the stock significantly.

There is also internal debate about the need for diversification beyond diabetes and obesity treatments. Novo Nordisk generated nearly 95 percent of its first-half 2026 sales from these areas, whereas competitors like Eli Lilly have expanded into neuroscience and immunology. Markus Manns, a portfolio manager at Union Investment, has called for a more sustainable growth strategy, though he remains hopeful for developments at an upcoming investor meeting.

Doustdar acknowledges the persistent comparisons to Eli Lilly but cautions against viewing the competition as an obsession. For him, the immediate focus lies in winning over physicians with the biological benefits of new drugs such as CagriSema and the forthcoming tetratriide, which Novo plans to seek U.S. approval for early next year.

Ultimately, Doustdar believes that time will be the key factor in shifting market sentiment. He described CagriSema as underestimated by investors and stressed that success hinges less on selling the product to financial markets than to the medical community that understands the science behind it. As Novo Nordisk navigates this critical juncture, the industry will be watching closely to see whether these strategic changes can restore growth and confidence in one of the world’s leading pharmaceutical companies.